PUBLIC COMPANY
save$CLYMClimb Bio, Inc.
$CLYMWellesley Hills, MA, USupdated 4mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- phase2A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
- phase1A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- phase2A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
- EP1A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
- phase1A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
🐶 Hiring Signal
News
- Ionis’ rare neurology drug approved; Pfizer inks an ADC dealZanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.biopharma_dive · 29d ago
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that